Hormonal Genetic Synergy-Induced Regression of Prostate Adenocarcinoma

Abstract

Hormonal therapy is the standard treatment for advanced androgen-dependent prostate adenocarcinoma. If tumor regression is not achieved early, the adenocarcinoma inevitably evolves toward androgen independence. This is due to the development of resistance mechanisms and the incomplete tissue-level cessation of androgen deprivation. Current research is focused on combined therapeutic strategies that will increase the effectiveness of androgen deprivation and delay recurrence. Androgen deprivation through hormonal therapy combined with genetic therapy can induce tumor regression by reducing angiogenesis and enhancing mitotic arrest and apoptosis. A study by the Intergroup in the United States has demonstrated a method for hormonal and genetic restoration of altered prostate cancer patterns resulting from intergenic suppression. This is due to mutations that alter the process by which the genetic information of a mutated gene is expressed. This highlights the urgent need to combine hormonal and genetic therapeutic approaches and expand our current understanding of molecular mechanisms. Epigenetic changes are considered key factors in prostate cancer treatment. Studies have shown that targeting epigenetic enzymes or regulatory proteins halts cancer cell division. Combining hormonal and genetic therapeutic approaches leads to induced regression of prostate adenocarcinoma.

Keywords: Hormonal Genetic Synergy; Induced Regression; Prostate Adenocarcinoma

Citation

Evgeniy Bryndin. Hormonal Genetic Synergy-Induced Regression of Prostate Adenocarcinoma. WebLog J Clin Case Rep. wjccr.2025.j2004. https://doi.org/10.5281/zenodo.17445644